2.50
Hdl Handle:
http://hdl.handle.net/10541/76294
Title:
Engineering T cells for cancer therapy.
Authors:
Mansoor, Was; Gilham, David E; Thistlethwaite, Fiona C ( 0000-0002-4832-7008 ) ; Hawkins, Robert E
Abstract:
It is generally accepted that the immune system plays an important role in controlling tumour development. However, the interplay between tumour and immune system is complex, as demonstrated by the fact that tumours can successfully establish and develop despite the presence of T cells in tumour. An improved understanding of how tumours evade T-cell surveillance, coupled with technical developments allowing the culture and manipulation of T cells, has driven the exploration of therapeutic strategies based on the adoptive transfer of tumour-specific T cells. The isolation, expansion and re-infusion of large numbers of tumour-specific T cells generated from tumour biopsies has been shown to be feasible. Indeed, impressive clinical responses have been documented in melanoma patients treated with these T cells. These studies and others demonstrate the potential of T cells for the adoptive therapy of cancer. However, the significant technical issues relating to the production of natural tumour-specific T cells suggest that the application of this approach is likely to be limited at the moment. With the advent of retroviral gene transfer technology, it has become possible to efficiently endow T cells with antigen-specific receptors. Using this strategy, it is potentially possible to generate large numbers of tumour reactive T cells rapidly. This review summarises the current gene therapy approaches in relation to the development of adoptive T-cell-based cancer treatments, as these methods now head towards testing in the clinical trial setting.
Affiliation:
Cancer Research UK, Department of Medical Oncology, University of Manchester, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Withington, Manchester, UK.
Citation:
Engineering T cells for cancer therapy. 2005, 93 (10):1085-91 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
14-Nov-2005
URI:
http://hdl.handle.net/10541/76294
DOI:
10.1038/sj.bjc.6602839
PubMed ID:
16251873
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMansoor, Was-
dc.contributor.authorGilham, David E-
dc.contributor.authorThistlethwaite, Fiona C-
dc.contributor.authorHawkins, Robert E-
dc.date.accessioned2009-08-04T17:29:54Z-
dc.date.available2009-08-04T17:29:54Z-
dc.date.issued2005-11-14-
dc.identifier.citationEngineering T cells for cancer therapy. 2005, 93 (10):1085-91 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid16251873-
dc.identifier.doi10.1038/sj.bjc.6602839-
dc.identifier.urihttp://hdl.handle.net/10541/76294-
dc.description.abstractIt is generally accepted that the immune system plays an important role in controlling tumour development. However, the interplay between tumour and immune system is complex, as demonstrated by the fact that tumours can successfully establish and develop despite the presence of T cells in tumour. An improved understanding of how tumours evade T-cell surveillance, coupled with technical developments allowing the culture and manipulation of T cells, has driven the exploration of therapeutic strategies based on the adoptive transfer of tumour-specific T cells. The isolation, expansion and re-infusion of large numbers of tumour-specific T cells generated from tumour biopsies has been shown to be feasible. Indeed, impressive clinical responses have been documented in melanoma patients treated with these T cells. These studies and others demonstrate the potential of T cells for the adoptive therapy of cancer. However, the significant technical issues relating to the production of natural tumour-specific T cells suggest that the application of this approach is likely to be limited at the moment. With the advent of retroviral gene transfer technology, it has become possible to efficiently endow T cells with antigen-specific receptors. Using this strategy, it is potentially possible to generate large numbers of tumour reactive T cells rapidly. This review summarises the current gene therapy approaches in relation to the development of adoptive T-cell-based cancer treatments, as these methods now head towards testing in the clinical trial setting.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntibodies-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy-
dc.subject.meshNeoplasms-
dc.subject.meshReceptors, Antigen, T-Cell-
dc.subject.meshT-Lymphocytes-
dc.subject.meshTissue Therapy-
dc.titleEngineering T cells for cancer therapy.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Department of Medical Oncology, University of Manchester, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.